AGENDA
| SPEAKER | TITLE | TIME |
| Francesca Buttini (University of Parma)
Cornelia Désirée Sonntag (Galenus Foundation) Prof. Paolo Martelli (University Rector) Prof. Gianni Galaverna (Head of Food and Drug Department) |
Conference opening | 9:00-9:25 |
NEW PARADIGMS IN LUNG DELIVERY
|
||
| David Edwards (Harvard University, US) | Chronic cough, airway rehydration, and climate change | 9:25-9:55 |
| Michael Hindle (Virginia Commonwealth University, US) | Development of a lung surfactant powder aerosol product for babies with respiratory distress syndrome | 9:55-10:20 |
| Pavan Muttil (University of New Mexico, US) | Formulation development and preclinical evaluation of aerosol vaccines: challenges, opportunities and lessons learnt | 10:20-10:45 |
|
COFFEE BREAK + POSTER SESSION |
||
| Nicola Tsapis (Paris-Saclay University, France) | Nanomedicines and microparticles for the treatment of pulmonary infections | 11:25-11:50 |
| David Cipolla (Insmed, US) | Preclinical and CMC development of treprostinil palmitil inhalation powder | 11:50-12:15 |
| Paul Hagedoorn (University of Groningen, The Netherlands) | The development of pulmonary levodopa applications for patients with Parkinson’s disease | 12:15-12:40 |
|
LIGHT LUNCH + POSTER SESSION |
||
RESPIRATORY TREE AS A SITE FOR THE DELIVERY OF BIOLOGICS
|
||
| Tomaso Guidi (Chiesi, Italy) | Inhaled biologics: current trends in the industry | 14:20-14:40 |
| Francesca Buttini (University of Parma, Italy) | The formulation of protein and probiotics in dry powder inhalers | 14:40-15:05 |
| To be selected from abstracts submitted | 15:05-15:20 | |
| To be selected from abstracts submitted | 15:20-15:35 | |
|
COFFEE BREAK + POSTER SESSION |
||
| Regina Scherließ (Kiel University, Germany) | Nasal vaccine technology | 16:15-16:40 |
| Ben Forbes (King’s College, UK) | Biologics from nose to brain | 16:40-17:05 |
| To be selected from the abstract submitted | 17:05-17:20 | |
|
WELCOME RECEPTION |
||
| SPEAKER | TITLE | TIME |
BIOLOGICS LOVE LUNGS
|
||
| Hugh Smyth (University of Texas at Austin, US) | Developing inhaled mAbs and nucleic acids for therapeutic success | 9:00-9:30 |
| Jenny Lam (University of Central London, UK) | How to make antibodies formulation stable and inhalable | 9:30-9:55 |
| To be selected from abstracts submitted | 9:55-10:10 | |
| To be selected from abstracts submitted | 10:10-10:25 | |
|
COFFEE BREAK + POSTER SESSION |
||
ENVIRONMENTAL PROTECTION BECOMES A REALITY IN THE DEVELOPMENT OF PMDI
|
||
| Barzin Gavtash and Benjamin Myatt (Kindeva, UK) | Atomization properties and aerosol characteristics of new low GWP propellants | 11:05-11:30 |
| Angelo Matturro (Chiesi, Italy) | Transition to LGWP propellant using HFA152a | 11:30-11:45 |
| David Lechuga (Astra Zeneca, US) | pMDI engineered particle suspensions in next generation propellants | 11:45-12:10 |
| Chris Baron (Aptar Pharma, France) | Key learnings and pathways forward. Circumnavigating the challenges of your low GWP pMDI transition programs | 12:10-12:25 |
| Sergio Monti (RxPack Italy) | Shifting tides: pMDI market scenarios into the low GWP propellant transition | 12:25-12:40 |
|
LIGHT LUNCH + POSTER SESSION |
||
LAST FRONTIERS IN LUNG INFECTION
|
||
| Keertan Dheda (University of Cape Town, South Africa) | Challenges in the prevention and management of drug-sensitive and drug-resistant Tuberculosis | 14:20-14:45 |
| Lea Ann Dailey (University of Vienna, Austria) | A liposomal strategy for inhaled bedaquiline: in vivo pharmacodynamics and pharmacokinetics | 14:45-15:10 |
| Francesca Ungaro (University of Naples, Italy) | Novel formulation approaches for lung infection treatment | 15:10-15:35 |
| Mirjam Kobler (H&T Presspart, UK) | The sunriser – achieving high performance in challenging formulations | 15:35-15:50 |
|
COFFEE BREAK + POSTER SESSION |
||
| PhD Students Contest Seven7th | Seven talks of 7 minutes selected from abstract submission | 16:20-17:20 |
|
|
||
| SPEAKER | TITLE | TIME |
NEW RESEARCH
|
||
| Federico Lavorini (University of Florence, Italy) | Physiological and technological barriers in the treatment of COPD | 9:00-9:30 |
| Jan de Backer (FLUIDDA, USA) | The role of digital twins and in-silico trials as regulatory tools for the authorization of orally inhaled drugs | 9:30-9:55 |
| Carsten Ehrhardt (Trinity College, Ireland) | Uptake mechanisms of molecules released into the lungs | 9:55-10:20 |
|
COFFEE BREAK + POSTER SESSION |
||
| Daniela Traini (Macquarie University, Australia) | Non-clinical tests in the evaluation of inhaled pharmaceuticals | 11:00-11:25 |
| Per Bäckmann (Emmace, Sweden) | Physiologically-based biopharmaceutical models- a tool to understand local and systemic exposure of inhaled medicines | 11:25-11:50 |
| Amrit Paude (Amrit Paude) | Empowering drug-drug co-amorphous inhaled formulation design using data-driven approach | 11:50-12:15 |
| Noémi Stefánia Csaba (University of Santiago de Compostela, Spain) | A multi-stage pulmonary drug delivery system based on sporopollenin | 12:15-12:40 |
|
CLOSING REMARKS |
||
AGENDA
Francesca Buttini (University of Parma), Cornelia Désirée Sonntag (Galenus Foundation), Prof. Paolo Martelli (University Rector), Prof. Gianni Galaverna (Head of Food and Drug Department)
Conference Opening
9:00-9:25
NEW PARADIGMS IN LUNG DELIVERY
David Edwards (Harvard University, US)
Title TBA
9:25-9:55
Michael Hindle (Virginia Commonwealth University, US)
Development of a Lung Surfactant Powder Aerosol Product for Babies with Respiratory Distress Syndrome
9:55-10:20
Pavan Muttil (University of New Mexico, US)
Formulation Development and Preclinical Evaluation of Aerosol Vaccines: Challenges, Opportunities and Lessons Learnt
10:20-10:45
COFFEE BREAK + POSTER SESSION
Nicola Tsapis (Paris-Saclay University, France)
Nanomedicines and microparticles for the treatment of pulmonary infections
11:25-11:50
David Cipolla (Insmed, US)
Preclinical and CMC Development of Treprostinil Palmitil Inhalation Powder (IPF)
11:50-12:15
Paul Hagedoorn (University of Groningen, The Netherlands)
The development of pulmonary levodopa applications for patients with Parkinson’s disease
12:15-12:40
LIGHT LUNCH + POSTER SESSION
RESPIRATORY TREE AS A SITE FOR THE DELIVERY OF BIOLOGICS
Tomaso Guidi (Chiesi, Italy)
Inhaled Biologics: current trends in the industry
14:20-14:40
Francesca Buttini (University of Parma, Italy)
The formulation of protein and probiotics in dry powder inhalers
14:40-15:05
To be selected from abstracts submitted
15:05-15:20
To be selected from abstracts submitted
15:20-15:35
COFFEE BREAK + POSTER SESSION
Regina Scherließ (Kiel University, Germany)
Nasal vaccine technology
16:15-16:40
Ben Forbes (King’s College, UK)
Biologics from nose to brain
16:40-17:05
To be selected from the abstract submitted
17:05-17:20
WELCOME RECEPTION
BIOLOGICS LOVE LUNGS
Hugh Smyth (University of Texas at Austin, US)
Developing inhaled mAbs and nucleic acids for therapeutic success
9:00-9:30
Jenny Lam (UCL, UK)
How to make antibodies formulation stable and inhalable
9:30-9:55
To be selected from abstracts submitted
9:55-10:10
To be selected from abstracts submitted
10:10-10:25
COFFEE BREAK + POSTER SESSION
ENVIRONMENTAL PROTECTION BECOMES A REALITY IN THE DEVELOPMENT OF PMDI
Barzin Gavtash (Kindeva, UK)
Atomization properties and aerosol characteristics of new low GWP propellants
11:05-11:30
Angelo Matturro (Chiesi, Italy)
Transition to LGWP propellant using HFA152a
11:30-11:45
David Lechuga (Astra Zeneca, US)
pMDI engineered particle suspensions in next generation propellants
11:45-12:10
Chris Baron (Aptar Pharma, France)
Key learnings and pathways forward. Circumnavigating the challenges of your low GWP pMDI transition programs
12:10-12:45
Sergio Monti (RxPack Italy) Shifting tides: pMDI market scenarios into the low GWP propellant transition
12:25-12:40
LIGHT LUNCH + POSTER SESSION
LAST FRONTIERS IN LUNG INFECTION
Keertan Dheda (University of Cape Town, South Africa)
Challenges in the prevention and management of drug-sensitive and drug-resistant Tuberculosis
14:20-14:45
Lea Ann Dailey (University of Vienna, Austria)
A liposomal strategy for inhaled bedaquiline: in vivo pharmacodynamics and pharmacokinetics
14:45-15:10
Francesca Ungaro (University of Naples, Italy)
Novel formulation approaches for lung infection treatment
15:10-15:35
Mirjam Kobler (H&T Presspart, UK)
The Sunriser – achieving high performance in challenging formulations
15:35-15:50
NEW RESEARCH
Federico Lavorini (University of Florence, Italy)
Physiological and Technological barriers in the treatment of COPD
9:00-9:30
Jan de Backer (FLUIDDA, USA)
The role of digital twins and in-silico trials as regulatory tools for the authorization of orally inhaled drugs
9:30-9:55
Carsten Ehrhardt (Trinity College, Ireland)
Uptake mechanisms of molecules released into the lungs
9:55-10:20
COFFEE BREAK + POSTER SESSION
Daniela Traini (Macquarie University, Australia)
Non-Clinical Tests in the Evaluation of Inhaled Pharmaceuticals
11:00-11:25
Per Backmann (Emmace, Sweden)
Physiologically-based biopharmaceutical models- a tool to understand local and systemic exposure of inhaled medicines
11:25-11:50
Amrit Paudel (RCPE, Austria)
Empowering drug-drug co-amorphous inhaled formulation design using datadriven approach
11:50-12:15
Noémi Stefánia Csaba (University of Santiago de Compostela, Spain)
A multi-stage pulmonary drug delivery system based on sporopollenin
12:15-12:40
CLOSING REMARKS
WELCOME RECEPTION
The Welcome Reception will be held on Wednesday, 11 September 2024 from 17:20 – 19:00 h at the Conference Venue (Auditorium del Carmine).
CONFERENCE DINNER
The Conference Dinner will be held on Thursday, 12 September 2024 at 19:00 h at Guazzatoio (Complesso Monumentale della Pilotta).
CONFIRMED SPEAKERS
